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Introduction Vulvar carcinoma is a rare disease accounting for only 5% of all gynecological malignancies [1] . Mainly elderly women are affected with a peak incidence in the eight decade [2] . Squamous cell carcinoma is the most common histological subtype and occurs in 90% of all vulvar carcinomas [3, 4] . Stage, tumor size, depth of invasion, vascular space invasion and especially lymph node metastases are important prognostic factors [3] . The 5-year survival is generally good for FIGO stage I (79%) but declines with more advanced stage of disease: stage II (59%), stage III (43%) and stage IV (13%) [2] . Surgery is the cornerstone of vulvar carcinoma treatment and consists of a wide local excision with uni-or bilateral inguinofemoral lymphadenectomy via separate incisions. An important improvement in vulvar cancer treatment was the introduction of sentinel node dissection in selected patients with early stage disease [5] . Adjuvant radiotherapy is indicated in patients with lymph node metastases [6] , and chemoradiation is a possibility for (locally) advanced vulvar carcinoma [7] .
Despite developments during the last years, improvement of treatment and prognosis of vulvar carcinoma patients is still needed. In this respect, immunotherapy might be an interesting new treatment option where it is generally recognized that the immune system has an important role in regulating cancer development [8] .
Cytotoxic T-lymphocytes (CTL) are important effector cells in the adaptive immune system, able to recognize cancer cells as "non-self" and subsequently kill them. Recognition of "non-self" by CTLs can only take place when antigenic peptides (which are derived from digested proteins and broken down in the proteasome of the cell and transported to the cell surface) are presented by the human leukocyte antigen (HLA) class I present at the cell surface of every nucleated cell. The importance of CTL as part of anti-tumor response was emphasized by studies in several cancers demonstrating an association between a high number of tumor-infiltrating CD8 + T-lymphocytes (CTL) and increased survival [9] [10] [11] [12] [13] [14] . However, cancer cells can develop several strategies to escape eradication by the immune system [15] . Downregulation of the HLA class I molecule is one such powerful mechanism, preventing immune recognition and lysis by CTLs. Another mechanism is the induction of regulatory T-lymphocytes (Tregs) which are known for their immunosuppressive function. Increasing evidence shows that Tregs play a major Gynecologic Oncology 125 (2012) [186] [187] [188] [189] [190] [191] [192] [193] role in modulating host response to tumors; by suppressing effector T-lymphocyte proliferation (i.e. CTL) an adequate tumor-specific immune response is prohibited. Increased numbers of intratumoral Tregs was associated with impaired prognosis in several malignancies [16] [17] [18] [19] [20] . Furthermore, the intracellular enzyme indoleamine 2,3-dioxygenase (IDO) is currently considered an important immune escape mechanisms in cancer. IDO catalyses the first and rate-limiting steps in the breakdown of the essential amino acid tryptophan along the kynurenine pathway where several downstream metabolites are formed [21] . IDO expression can occur in several cell types (e.g. dendritic cells or cancer cells) after induction by IFN-γ or lipopolysaccharide. IDO exerts its immunosuppressive function by suppressing effector T-lymphocytes and natural killer (NK) cells. Our group recently showed that IDO activity is significantly increased in serum of patients with endometrial, ovarian and vulvar cancer compared to healthy controls [22] .
In vulvar carcinoma, evidence for the (prognostic) role of the immune system in vulvar carcinoma is scarce [23, 24] and research is warranted on this subject. Therefore, this study aimed to determine the prognostic role of several aspects of the immune system in vulvar carcinoma patients. Therefore, the presence and prognostic influence of two important subsets of T-lymphocytes (CD8 + and Foxp3 + T-lymphocytes), next to HLA class I downregulation and IDO expression were determined in a large and consecutively selected cohort of patients with vulvar carcinoma.
Materials and methods

Patients
Tissue samples of all patients with gynecological malignancies treated at the Department of Gynecological Oncology of the University Medical Center Groningen (UMCG) are prospectively collected and stored in the tissue storage system of the Department of Pathology of the UMCG, the Netherlands. Clinicopathological characteristics and follow-up data of all these patients are prospectively collected during standard treatment and follow-up and stored in a computerized registration database. For the present study, tissue material and data of clinicopathological characteristics of patients with vulvar carcinoma were used as reported previously [25] . Patients had been consecutively selected when treated for squamous cell carcinoma of the vulva in the UMCG between 1984 and 2001. Patients were excluded when treated with a histological subtype other than squamous cell carcinoma or if they had been treated with preoperative radiotherapy. Staging was performed according to the surgicopathological FIGO classifications applicable at that time [26] and the AJCC TNM classification [27] . Follow-up data were updated until July 2010.
Institutional review board approval
All relevant data were retrieved from our computerized database into a separate, anonymous, password protected database. Patient identity was protected by study specific, unique patient codes, which were only known to two dedicated data managers, who also have responsibility for the larger database. In case of uncertainties with respect to clinicopathological and follow-up data, the larger databases could only be checked through the data managers, thereby ascertaining the protection of patients' identity. Due to these procedures, according to Dutch law no further patient or institutional review board approval was needed.
Immunohistochemistry
For staining, 4-μm sections were cut from previously constructed tissue microarrays of formalin-fixed paraffin-embedded tumors [25] and applied to 3-amino-propyl-triethoxy-silane coated glass slides (Sigma-Aldrich, Diesenhofen, Germany). For immunostaining, tissue microarray slides were first dewaxed and rehydrated. Methods and antibodies for immunostaining of CD8 + T-lymphocytes, Foxp3 + T-lymphocytes, HLA-B/C and β 2 m were used as previously reported [22, 28] . For HLA-A and IDO, antigen retrieval was performed by microwave treatment; 15 min in citrate (pH 6.0) (HLA-A), and EDTA buffer (pH 8.0) (IDO). Endogenous peroxidase activity was blocked with 0.3% H 2 O 2 for 30 min after which the slides were incubated with the primary antibodies for 60 min at room temperature (dilutions 1:100); HCA2 recognizing the HLA class I heavy chain HLA-A (kindly provided by Prof., Dr. J.J. Neefjes, The Netherlands Cancer Institute, Amsterdam, The Netherlands), and a mouse monoclonal antibody recognizing IDO (anti-indoleamine 2,3-dioxygenase, clone 10.1; Millipore (Chemicon)) were used. Sections were incubated with RAM po (rabbit anti-mouse peroxidase-labeled) and GAR po (goat antirabbit peroxidase-labeled) (DAKO, Heverlee, Belgium, 1:100). Antigenantibody reactions were visualized with 3,3-diaminobenzidine and sections were counterstained with haematoxylin.
Evaluation of immunohistochemistry staining
Immunohistochemistry stained slides were scored independently by two investigators (RJ and NT) when at least 2 cores per case were present, each containing at least 20% tumor tissue. The number of positively stained intratumoral CD8 + and Foxp3 + T-lymphocytes was counted and the average number was calculated per 0.283 mm 2 of tumor (i.e. one whole core consisting of 100% tumor tissue) (Figs. 1A and B) [9, 10] . IDO expression was assessed according to a semi-quantitative scale which is based on the extent and intensity of the staining [29] . Intensity of the cytoplasmic staining was scored as 0 for absent, 1 for weak, 2 for positive or 3 for strong positive expression. The percentage was scored as 0 for 0-5%; 1 for ≥5-30%; 2 for ≥30-70% and 3 for ≥70-100%. The sum of scores was used to identify four categories of expression: IDO A semiquantitative scoring system was also used for HC-10, HC-A2 and β 2 -m expression. Intensity of the membrane staining was scored as 0 for absent; 1 for weak; 2 for positive or 3 for strong positive expression. The percentage was scored as 0 for 0%; 1 for ≥1-5%; 2 for ≥5-25%; 3 for ≥25-50%; 4 for ≥50-75% and 5 for ≥75-100%. The sum of both scores was used to identify three categories of expression: normal expression (6.5-8), partial loss (2.5-6.5) and total loss (0-2.5) (Figs. 1E-M). Mean result of the cores was considered as definitive HC-10, HC-A2 and β 2 -m expression.
Statistical analysis
All continuous variables were tested for normality. In case of skewed distributions, the median and interquartile ranges (IQR, 25th to 75th percentile) were presented. Staining of HLA class I was dichotomized; partial loss and normal expression were taken together and compared to total loss of expression. Associations between clinicopathological characteristics (see Table 1 ) and the number of CD8 + T-lymphocytes, Foxp3 + T-lymphocytes (dichotomized according to their median), IDO, HLA-A, HLA-B/C and β 2 -m expression was estimated using univariate logistic regression analyses. Clinicopathological parameters were used as independent and T-lymphocytes, IDO expression and HLA class I components were used as dependent variables. Odds Ratios (ORs) and 95%-confidence intervals (95%-CI) were estimated. Univariate and multivariate Cox proportional hazard analysis were used to assess influence of clinicopathological characteristics, numbers of CD8 + T-lymphocytes and Foxp3 + T-lymphocytes and expression levels of IDO, HLA-A, HLA-B/C and β 2 -m on survival. Disease-free survival (DFS) was defined as date of diagnosis until recurrent disease, metastasis, death due to vulvar cancer or last date of follow-up. Disease specific survival (DSS) was defined as date of diagnosis until death due to vulvar carcinoma or the date of last follow-up. Clinicopathological characteristics and immunohistochemistry expression were used as independent and recurrent disease (DFS) or death of disease (DSS) were used as dependent variables. Hazard Ratios (HRs) and 95%-CIs were calculated. Variables with a p value b0.05 in univariate analysis were simultaneously entered into the multivariate model. All tests were performed twosided and p values of b0.05 were considered statistically significant. Analyses were performed using SPSS software version 16.0 (SPSS Inc, Chicago, USA).
Results
Patients
In total, 286 patients with vulvar carcinoma were included in this study of whom clinicopathological characteristics are depicted in Table 1 . Median age at time of diagnosis was 73 years (IQR: 63-81 years). The majority of the patients were diagnosed with a T2 tumor (74.1%). The tumor was localized unilateral in 84.3% and multifocality was observed in 15.7%. One or more inguinofemoral metastasis were present in 40.1% of the patients whereas 59.9% did not show inguinofemoral metastasis. HLA class I downregulation Downregulation of HLA-A, HLA-B/C or β 2 -m was observed in 37.9%, 11.1% and 2.2%, respectively. Age and positive vascular invasion were associated with HLA-A downregulation and poorly differentiated tumors were associated with HLA-B/C downregulation (Table 3 
IDO expression
IDO expression was present in 50.4% of the cases. As shown by means of univariate logistic regression analysis (Table 3) , no associations were found between clinicopathological characteristics, HLA class I downregulation, the number of T-lymphocytes and IDO expression.
Survival
Median time of follow-up was 73 months (IQR: 0-290 months). In 98 patients (32.6%), recurrence of disease was diagnosed with a median time until recurrence of 23 months (IQR: 7.0-65.0 months). In total, 76 patients (25.5%) died as a result of vulvar carcinoma during our followup.
In univariate analyses on DFS, only the presence of inguinofemoral metastasis was significantly related to a shorter DFS (Table 4) .
In univariate analyses on DSS, inguinofemoral metastasis, T2 tumor, a high tumor grade, positive vascular invasion and infiltration depth >5 mm were predictors for a worse DSS, in order of importance (Table 5) . In multivariate analysis, inguinofemoral metastasis, T2 tumor, a high tumor grade and positive vascular invasion were independent predictors for a shorter DSS.
The number of CD8 + T-lymphocytes and Foxp3 + T-lymphocytes, HLA class I downregulation, IDO expression were not related to DSS.
Discussion
In this large and well-documented cohort of 286 patients with vulvar carcinoma, we evaluated the prognostic significance of several aspects of the immune system. We showed that the number of CD8 + T-lymphocytes was significantly related to HLA class I downregulation which reflects the natural mechanism of this interaction. However, the number of intratumoral CD8 + T-lymphocytes or Foxp3 + Tlymphocytes, HLA class I downregulation and IDO expression were not associated with survival. Our results indicate that the immune system does not seem to have a major influence on prognosis of patients with vulvar carcinoma. The prognostic influence of tumor-infiltrating T-lymphocytes and more specifically, CD8 + and Foxp3 + T-lymphocytes has been studied in several cancer types. In this cohort of 286 vulvar carcinoma patients, intra-tumoral CD8 + and Foxp3 + T-lymphocytes were present in 96.3% and 95.1% of the cases. In agreement with results of a recently published study in vulvar carcinoma [23] , we did not find an association between the number of T-lymphocytes and survival of vulvar carcinoma patients. This result is in contrast with studies previously performed in endometrial [9, 11] , ovarian [10, 30] and cervical carcinoma [31] . In this study, vulvar carcinomas with infiltration depth of >5 mm were associated with a high number of CD8 + T-lymphocytes and a Younger patients with vulvar carcinoma more frequently showed downregulation of HLA-A. Furthermore, positive vascular invasion was associated with HLA-A downregulation, and poorly differentiated tumors were associated with HLA-B/C downregulation. These results suggest an association between poor prognostic factors and downregulation of HLA class I. However, HLA class I downregulation did not have a significant influence on survival of patients with vulvar carcinoma. These results are in contrast to studies in endometrial [28] , ovarian [33, 34] and cervical cancer [31, 35] where an association between downregulation of HLA class I and poor prognosis was observed.
IDO is currently considered an important immune escape mechanism in cancer. We have recently shown that IDO activity is significantly increased in serum of patients with vulvar cancer [22] , suggesting that IDO also plays a role in vulvar carcinoma. IDO expression has been associated with decreased prognosis in several cancer types In contrast to results of a recent study in 76 vulvar carcinoma patients [24] , we did not find an association between IDO expression and clinicopathological characteristics or survival. The intracellular enzyme IDO functions as an immune escape mechanism by means of suppressing T-lymphocytes and NK cells and therefore we expected an inverse relation between the number of CD8 + Tlymphocytes and IDO expression. However, we did not observe such a relation. These results suggest that the immune system has a different function in vulvar carcinoma compared to other gynecological malignancies such as endometrial, ovarian and cervical cancer. Possibly, the fact that vulvar carcinoma is localized on the skin might cause these differences. One other explanation might be the fact that patients diagnosed with vulvar carcinoma are generally older compared to patients diagnosed with endometrial, ovarian or cervical cancer. Aging is associated with a change in immune activation, especially of the T-cell/macrophage system. Due to an IFN-γ dependent increase of IDO activity amongst elderly, infections, autoimmune diseases and malignancies occur more often [36] . The presence of inguinofemoral metastasis was the only factor which significantly related to a shorter DFS. Furthermore, the presence of inguinofemoral metastasis was an independent predictor for a worse DSS, next to a T2 tumor, poorly/undifferentiated differentiated tumor and positive vascular invasion. These results are in agreement with previous studies determining the prognostic role of several surgicopathological characteristics in patients with vulvar carcinoma [3] .
This study evaluated the presence and prognostic influence of important players in cellular immunity and to our knowledge, we are the first to evaluate HLA class I downregulation in vulvar carcinoma. We were able to evaluate immunohistochemistry expression on tissue material of a unique large number (n = 286) of vulvar carcinoma patients, all treated with primary surgery in a single institution (UMCG, Groningen, the Netherlands). In order to evaluate this large series of specimens in a high-throughput manner, we used a previously constructed tissue microarray [25] . This method is widely used in cancer research and was recently validated for vulvar carcinoma [37] . Our results showed that none of these immunological parameters have a significant influence on survival of vulvar carcinoma patients, in contrast to results of studies in several other cancer types. However, as there is a relationship between effect and study size, we believe that our (negative) results in a large cohort of patients is of major importance [13] . In summary, the current study investigated the presence and prognostic impact of several immunological factors in vulvar carcinoma patients. The number of tumor-infiltrating CD8 + and Foxp3 + T-lymphocytes, HLA class I downregulation and IDO expression were not related to survival in our population. The presence of inguinofemoral metastasis was one of the "classical" prognostic characteristics associated with poor survival and is of major importance in determining prognosis and adequate treatment strategies in patients with vulvar carcinoma. Although our results suggest that important players in the adaptive immune system do not seem to have an influence on survival, these results need to be confirmed (or rejected) by future research. Attempts have been made to identify tumor associated antigens as possible targets in vulvar carcinoma [38] . Hopefully, this will lead to more research concerning targeted therapy in an approach to improve prognosis of vulvar carcinoma patients.
